ARID1A intact or deficient BRAFV600E melanoma after vemurafenib resistance.
The project investigates tumor neoantigens derived from ARID1A deficient BRAFV600E melanomas classified by vemurafenib (BRAFV600E inhibitor) resistance in experimental setting. Wild type (WT) BRAFV600E Ptennull melanoma cells were established from spontaneous melanoma developing mice model. ARID1A knockout (KO) cells were generated by CRISPR-Cas9. Vemurafenib resistant (+R) cells were generated under the selection of vemurafenib for 8 weeks. Exome derived from cultured cells and RNA derived from tumor tissues implanted in mice (C57BL/6J) sequencing of mouse BRAFV600E melanoma cells, i.e., WT, WT+R, KO, and KO+R, were deposited. By using 888-mel cells, a human BRAFV600E melanoma cell line, we also examined human potential neoantigens. Three ARID1A knockout clones (KO1, KO2, KO3) were generated by CRISPR-Cas9. WT and KO clones were cultured under vemurafenib for 16 weeks to establish vemurafenib resistant (+R) clones. RNA sequencing of 888-mel cells, i.e., WT, WT+R, KO1, KO1+R, KO2, KO2+R, KO3, and KO3+R, were deposited.